Open AccessEarly Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort
Author(s) -
Peter Bossuyt,
Filip Baert,
F D’Heygere,
A. Nakad,
Cathérine Reenaers,
Fernand Fontaine,
Denis Franchimont,
Olivier Dewit,
Philippe Van Hootegem,
S Vanden Branden,
Guy Lambrecht,
Marc Ferrante,
Pieter Hindryckx,
Elisabeth Macken,
Philip Caenepeel,
A Vijverman,
Nicolas de Suray,
Joris Dutré,
Édouard Louis,
Jean-Louis Coenegracths
Publication year - 2018
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izy219
Subject(s) - golimumab , ulcerative colitis , medicine , cohort , gastroenterology , cohort study , colitis , infliximab , disease
Golimumab (GOL) is registered for moderate to severely active ulcerative colitis (UC). Data on the use of GOL in daily clinical practice are limited. Currently, it is unclear which factors are predictive of a favorable outcome. The goals of this study were to evaluate the mid-term outcome of GOL (week 26) in patients with moderate to severe UC and to determine predictors of favorable outcome.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom